Munich – Formycons commercialization partner Coherus BioSciences, Inc. announced that sales of CIMERLI® (ranibizumab-eqrn) to retinal specialists in the United States of America (“U.S.”) have exceeded 100,000 doses since commercial launch on October 3, 2022.

CIMERLI® is the first and only FDA-approved biosimilar interchangeable with Lucentis®3 for both strengths. In August 2023, CIMERLI® achieved 25% market share of the ranibizumab market, making it the number one ranibizumab biosimilar in the United States (“U.S.”).

“This is a great achievement and underlines again that biosimilars are an important treatment option for severe retinal diseases. With FYB201, we have developed an excellent product, which has now become number one ranibizumab biosimilar in the U.S. market. We are also fully on track with our next two late-stage assets. File Acceptance by the U.S. Food and Drug Administration (“FDA”) for FYB203 (Eylea®4 biosimilar candidate) has already been reported and submission to the European Medicines Agency (“EMA”) is also planned in the course of this year. The same applies for FYB202 (Stelara®5 biosimilar candidate) which has already been accepted by the EMA and is fully on schedule regarding FDA submission,” commented Dr. Stefan Glombitza, CEO of Formycon AG.

1)CIMERLI® is a registered Trademark of Coherus BioSciences, Inc.
2) IQVIA NSP Data August 2023
3) Lucentis® is a registered Trademark of Genentech Inc
4)Eylea® is a registered Trademark of Regeneron Pharmaceuticals Inc.
5)Stelara® is a registered Trademark of Johnson & Johnson